Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 9805609, 8 pages
https://doi.org/10.1155/2017/9805609
Research Article

Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia

1University of Eastern Finland and Eastern Finland Laboratory Centre, Kuopio, Finland
2Kuopio University Hospital, Kuopio, Finland
3University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland

Correspondence should be addressed to Kari Pulkki; if.feu@ikklup.irak

Received 10 May 2017; Accepted 28 June 2017; Published 6 August 2017

Academic Editor: Silvia Angeletti

Copyright © 2017 Sini Korpelainen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Clarke, T. Jenyon, V. van Hamel Parsons, and A. J. King, “Neutropenic sepsis: management and complications,” Clinical Medicine (London, England), vol. 13, no. 2, pp. 185–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Suberviola, A. Marquez-Lopez, A. Castellanos-Ortega, C. Fernandez-Mazarrasa, M. Santibanez, and L. M. Martinez, “Microbiological diagnosis of sepsis: polymerase chain reaction system versus blood cultures,” American Journal of Critical Care, vol. 25, no. 1, pp. 68–75, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hämäläinen, A. Juutilainen, I. Matinlauri et al., “Serum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a comparison with C-reactive protein,” European Journal of Haematology, vol. 83, no. 3, pp. 251–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Sakr, C. Sponholz, F. Tuche, F. Brunkhorst, and K. Reinhart, “The role of procalcitonin in febrile neutropenic patients: review of the literature,” Infection, vol. 36, no. 5, pp. 396–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Westwood, B. Ramaekers, P. Whiting et al., “Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis,” Health Technology Assessment, vol. 19, no. 96, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Zhang, Z. D. Hu, J. Song, and J. Shao, “Diagnostic value of presepsin for sepsis: a systematic review and meta-analysis,” Medicine (United States), vol. 94, no. 47, article e2158, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Mussap, A. Noto, M. Fravega, and V. Fanos, “Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 24, Supplement 2, pp. 12–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Chenevier-Gobeaux, D. Borderie, N. Weiss, T. Mallet-Coste, and Y. E. Claessens, “Presepsin (sCD14-ST), an innate immune response marker in sepsis,” Clinica Chimica Acta, vol. 450, pp. 97–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Pugni, C. Pietrasanta, S. Milani et al., “Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates,” PLoS One, vol. 10, no. 12, article e0146020, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. G. L. Su, K. Dorko, S. C. Strom, A. K. Nüssler, and S. C. Wang, “CD14 expression and production by human hepatocytes,” Journal of Hepatology, vol. 31, no. 3, pp. 435–442, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Landmann, W. Zimmerli, S. Sansano et al., “Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock,” The Journal of Infectious Diseases, vol. 171, no. 3, pp. 639–644, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Burgmann, S. Winkler, G. J. Locker et al., “Increased serum concentration of soluble CD14 is a prognostic marker in gram-positive sepsis,” Clinical Immunology and Immunopathology, vol. 80, no. 3, pp. 307–310, 1996. View at Publisher · View at Google Scholar
  13. R. Landmann, A. M. Reber, S. Sansano, and W. Zimmerli, “Function of soluble CD14 in serum from patients with septic shock,” The Journal of Infectious Diseases, vol. 173, no. 3, pp. 661–668, 1996. View at Publisher · View at Google Scholar
  14. N. Hiki, D. Berger, C. Prigl et al., “Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria,” Infection and Immunity, vol. 66, no. 3, pp. 1135–1141, 1998. View at Google Scholar
  15. R. Berner, B. Fürll, F. Stelter, J. Dröse, H. P. Müller, and C. Schütt, “Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 2, pp. 440–445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. L. Kitchens and P. A. Thompson, “Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins,” Journal of Endotoxin Research, vol. 9, no. 2, pp. 113–118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Aalto, A. Takala, H. Kautiainen, S. Siitonen, and H. Repo, “Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection,” Scandinavian Journal of Infectious Diseases, vol. 39, no. 6-7, pp. 596–603, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. B. B. de Aguiar, I. Girardi, D. D. Paskulin et al., “CD14 expression in the first 24h of sepsis: effect of -260C>T CD14 SNP,” Immunological Investigations, vol. 37, no. 8, pp. 752–769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Rios-Toro, M. Marquez-Coello, J. M. Alvarez et al., “Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock,” PLoS One, vol. 12, no. 4, article e0175254, 2017. View at Publisher · View at Google Scholar
  20. J. Wu, L. Hu, G. Zhang, F. Wu, and T. He, “Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis,” PLoS One, vol. 10, no. 7, article e0133057, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Zheng, L. Jiang, L. Ye, Y. Gao, L. Tang, and M. Zhang, “The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis,” Annals of Intensive Care, vol. 5, no. 1, p. 48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Urbonas, A. Eidukaite, and I. Tamuliene, “The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia,” Cytokine, vol. 62, no. 1, pp. 34–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Olad, I. Sedighi, A. Mehrvar et al., “Presepsin (sCD14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia,” Iranian Journal of Pediatrics, vol. 24, no. 6, pp. 715–722, 2014. View at Google Scholar
  24. H. Koh, M. Aimoto, T. Katayama et al., “Diagnostic value of levels of presepsin (soluble CD14-subtype) in febrile neutropenia in patients with hematological disorders,” Journal of Infection and Chemotherapy, vol. 22, no. 7, pp. 466–471, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. W. T. Hughes, D. Armstrong, G. P. Bodey et al., “2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer,” Clinical Infectious Diseases, vol. 34, no. 6, pp. 730–751, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. R. C. Bone, R. A. Balk, F. B. Cerra et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” Chest, vol. 101, no. 6, pp. 1644–1655, 1992. View at Publisher · View at Google Scholar
  27. M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference,” Intensive Care Medicine, vol. 29, no. 4, pp. 530–538, 2003. View at Publisher · View at Google Scholar
  28. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012,” Intensive Care Medicine, vol. 39, no. 2, pp. 165–228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (sepsis-3),” Journal of the American Medical Association, vol. 315, no. 8, pp. 801–810, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. C. L. Sprung, R. M. Schein, and R. A. Balk, “The new sepsis consensus definitions: the good, the bad and the ugly,” Intensive Care Medicine, vol. 42, no. 12, pp. 2024–2026, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Hämäläinen, A. Juutilainen, T. Kuittinen et al., “Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein,” Leukemia & Lymphoma, vol. 51, no. 6, pp. 1040–1046, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Juutilainen, S. Hämäläinen, K. Pulkki et al., “Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis,” Leukemia & Lymphoma, vol. 52, no. 12, pp. 2349–2355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Juutilainen, M. Vänskä, K. Pulkki et al., “Pentraxin 3 predicts complicated course of febrile neutropenia in haematological patients, but the decision level depends on the underlying malignancy,” European Journal of Haematology, vol. 87, no. 5, pp. 441–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Vänskä, I. Koivula, S. Hämäläinen et al., “High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients,” Haematologica, vol. 96, no. 9, pp. 1385–1389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. K. Purhonen, M. Vänskä, S. Hämäläinen et al., “Plasma copeptin in the assessment of febrile neutropenia,” Peptides, vol. 36, no. 1, pp. 129–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Vänskä, I. Koivula, E. Jantunen et al., “IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients,” Cytokine, vol. 60, no. 3, pp. 787–792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Vänskä, A. K. Purhonen, I. Koivula et al., “Soluble form of urokinase-type plasminogen activator receptor as a diagnostic and prognostic marker in hematological patients with neutropenic fever,” Leukemia & Lymphoma, vol. 55, no. 3, pp. 718–721, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. Purhonen, A. Juutilainen, M. Vänskä et al., “Human plasma cell-free DNA as a predictor of infectious complications of neutropenic fever in hematological patients,” Infectious Diseases, vol. 47, no. 4, pp. 255–259, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Bas, B. R. Gauthier, U. Spenato, S. Stingelin, and C. Gabay, “CD14 is an acute-phase protein,” Journal of Immunology, vol. 172, no. 7, pp. 4470–4479, 2004. View at Google Scholar
  40. C. Chenevier-Gobeaux, E. Trabattoni, M. Roelens, D. Borderie, and Y. E. Claessens, “Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values?” Clinica Chimica Acta, vol. 427, pp. 34–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Masson, P. Caironi, C. Fanizza et al., “Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial,” Intensive Care Medicine, vol. 41, no. 1, pp. 12–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Nagata, Y. Yasuda, M. Ando et al., “Clinical impact of kidney function on presepsin levels,” PLoS One, vol. 10, no. 6, article e0129159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Poesen, A. Ramezani, K. Claes et al., “Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1525–1533, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Behnes, T. Bertsch, D. Lepiorz et al., “Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment,” Critical Care, vol. 18, no. 5, p. 507, 2014. View at Publisher · View at Google Scholar · View at Scopus